Warning: mt_rand(): max(-1) is smaller than min(0) in /www/wwwroot/friendsintechnology.com/PVtraffic/Setting.php on line 34

A new government study shows that the New Crown vaccine produced by Pfizer Inc. (PFE) and its partner BioNtech SE was highly effective in reducing the risk of severe disease in children 17 and younger during a surge in Omicron infections, but was less effective in preventing the infection.

The two-dose vaccine reduced the risk of hospitalization for new coronary pneumonia by 74 percent in children ages 5 to 11 and by 92 percent or more in children ages 12 to 17, according to the study released Tuesday by The Centers for Disease Control and Prevention (CDC).

However, according to the study, the vaccine was 51% effective in reducing the risk of neocrown (primarily omikron) infection in children 5 to 11 years of age and 34%-45% effective in children 12 to 17 years of age, depending on age, in the first five months after the second dose.

By admin

Leave a Reply

Your email address will not be published.